ClinicalTrials.gg

TargetBeta

ERBB3

erb-b2 receptor tyrosine kinase 3 · also HER3, LCCS2 · Erb-b2 receptor tyrosine kinases

12 programs in company-led studies act on ERBB3, from 11 companies: 5 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (9 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 35555 runningEGFRa judged reading
patritumab deruxtecanMerckphase 31715 running–a judged reading
beruzatatug pelitecanruleMediLink Therapeutics (Suzhou)phase 399 running–NCIt
ruzaltatug rezetecanJiangsu HengRui Medicinephase 387 running–the company's pipeline
JSKN016ruleAlphamab Oncologyphase 355 runningTACSTD2the studies' text
SYS6023ruleCSPC Pharmaceutical Groupphase 222 running–the studies' text
Anti-EGFR/Anti-HER3 Bispecific Antibody-drug Conjugate AVZO-1418ruleAvenzo Therapeuticsphase 211 runningEGFRNCIt
Anti-HER3/Anti-MUC1 Bispecific Antibody-drug Conjugate DM002ruleXadcera Biopharmaceutical (Suzhou)phase 211 runningMUC1NCIt
Anti-HER3/Exatecan Antibody-drug Conjugate ENV-501ruleHummingbird Biosciencephase 211 running–NCIt
KHN922ruleChengdu Kanghong Pharmaceutical Groupphase 211 running–the studies' text
CS5007ruleCStone Pharmaceuticalsphase 111 runningEGFRthe studies' text
JSKN016HCruleAlphamab Oncologyphase 111 runningTACSTD2the studies' text

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.